Get the Stockscreener App
0.7009
0.31%
-0.0022
Xilio Therapeutics Inc stock is traded at $0.7009, with a volume of 132.41K.
It is down -0.31% in the last 24 hours and up +0.60% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.7031
Open:
$0.7005
24h Volume:
132.41K
Relative Volume:
0.24
Market Cap:
$36.33M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2368
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
-0.86%
1M Performance:
+0.60%
6M Performance:
-21.34%
1Y Performance:
-22.32%
1-Day Range:
$0.6701
$0.702
1-Week Range:
$0.6406
$0.7272
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.7009 | 36.61M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.91 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.32 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.36 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
685.86 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
311.30 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Technical Models Suggest Xilio Therapeutics Inc. May Rebound Soon2025 Market Overview & Expert Verified Movement Alerts - mustnews.co.kr
Xilio Therapeutics Reports Q2 Earnings with Promising Pipeline Progress and Financial Results - AInvest
Xilio Therapeutics Reports Strong Pipeline Progress and Financial Results - TipRanks
Xilio Therapeutics Q2 2025 Earnings Miss Fails to Deliver, but Short-Term Price Action Shows Promise - AInvest
Xilio Therapeutics Q2 2025 Earnings Miss: Mixed Market Impact Amid Biotech Sector Resilience - AInvest
Does Xilio Therapeutics Inc. align with a passive investing strategy2025 Price Action Summary & Low Risk Investment Opportunities - thegnnews.com
Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024) - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Clover Health Investments (CLOV) and Xilio Therapeutics (XLO) - The Globe and Mail
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates - MSN
Xilio Therapeutics shares fall 1.27% after-hours following Q2 pipeline progress and business updates. - AInvest
Xilio Revenue Jumps 246 Percent in Q2 - AOL.com
Xilio Therapeutics 2025 Q2 Earnings Improved EPS Amid Wider Net Loss - AInvest
Xilio Therapeutics Q2 Earnings Beat Expectations, Revenue Doubles to $8.084M. - AInvest
Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest
Xilio Therapeutics Reports Q2 Loss, Misses Revenue Estimates: Stock Expected to Underperform Market - AInvest
Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Xilio Therapeutics, Inc. SEC 10-Q Report - TradingView
Xilio Therapeutics Q2 2025 Financial Results and Business Updates - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire
Cancer Drug Breakthrough: Xilio's Vilastobart Delivers Strong Results with Fewer Side Effects - Stock Titan
Heatmap analysis for Xilio Therapeutics Inc. and competitorsTrade Plan With Low Risk High Return - Newser
Brokers Issue Forecasts for XLO Q2 Earnings - Defense World
Advanced analytics toolkit walkthrough for Xilio Therapeutics Inc.Free Stock Market Watch With Alerts - Newser
Analyzing drawdowns of Xilio Therapeutics Inc. with statistical toolsAsset Allocation Summary With Future Outlook - Newser
Leerink Partners Initiates Coverage on Xilio Therapeutics with Outperform Rating, Sets Price Target of $2.00 - AInvest
How to use Fibonacci retracement on Xilio Therapeutics Inc.Momentum Entry Alerts with Risk Control - Newser
Using Bollinger Bands to evaluate Xilio Therapeutics Inc.Free High Conviction Intraday Stock Signals - Newser
Leerink Partners Maintains Xilio Therapeutics(XLO.US) With Buy Rating, Maintains Target Price $2 - 富途牛牛
Leerink Partners Begins Coverage on Xilio Therapeutics (NASDAQ:XLO) - Defense World
Xilio Therapeutics (XLO) Projected to Post Quarterly Earnings on Thursday - Defense World
Leerink Partners Initiates Coverage on Xilio Therapeutics with Outperform Rating - AInvest
Leerink Partners Initiates Xilio Therapeutics(XLO.US) With Buy Rating, Announces Target Price $2 - 富途牛牛
Xilio Therapeutics shares rise 4.95% premarket after Leerink Partners initiates coverage with an Outperform rating. - AInvest
Leerink Partners Initiates Xilio Therapeutics at Outperform With $2 Price Target - MarketScreener
Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating - Investing.com India
Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Xilio Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Xilio Therapeutics shares rise 2.77% intraday after Catalyst Pharmaceuticals appoints new board member. - AInvest
When is Xilio Therapeutics Inc. stock expected to show significant growthCapitalize on market shifts before others do - Jammu Links News
What institutional investors are buying Xilio Therapeutics Inc. stockUnlock powerful investment tools for free - Jammu Links News
What makes Xilio Therapeutics Inc. stock price move sharplyAchieve consistent profits with smart trading - Jammu Links News
Is Xilio Therapeutics Inc. a growth stock or a value stockAchieve rapid wealth accumulation through smart investing - Jammu Links News
Why is Xilio Therapeutics Inc. stock attracting strong analyst attentionAccelerated wealth expansion - Jammu Links News
What are Xilio Therapeutics Inc. company’s key revenue driversMaximize gains with proven stock analysis - Jammu Links News
What is Xilio Therapeutics Inc. company’s growth strategyIdentify winners with top-tier analysis - Jammu Links News
What are the latest earnings results for Xilio Therapeutics Inc.Maximize returns with effective portfolio management - Jammu Links News
Xilio Therapeutics Inc. Stock Analysis and ForecastNavigate the market with precision tools - Jammu Links News
MACD Cross Could Confirm Trend in Xilio Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What is the risk reward ratio of investing in Xilio Therapeutics Inc. stockMarket Forecast Data Feed From AI Tools - Jammu Links News
Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xilio Therapeutics Inc Stock (XLO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | Director |
Jun 17 '25 |
Buy |
0.69 |
25,000 |
17,215 |
70,000 |
| Russo Rene | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
0.68 |
36,289 |
24,680 |
281,172 |
| Frankenfield Christopher James | Chief Financial Officer |
Jan 02 '25 |
Sale |
0.98 |
6,954 |
6,841 |
12,421 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING |
Jan 02 '25 |
Sale |
0.98 |
1,803 |
1,774 |
3,197 |
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 18 '24 |
Buy |
1.04 |
1,759,978 |
1,830,377 |
9,105,451 |
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):